BioSpace News Archive

Histogen Inc. (NASDAQ: HSTO), today announced the initiation of its Phase 1/2 clinical trial of HST 003 to evaluate the safety and efficacy of human extracellular matrix (hECM:HST 003) implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.

Tiziana Life Sciences plc announces an interview with the Chairman of its’ Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST.

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of pharmaceutical industry leader Catherine Mackey, Ph.D., to its Board of Directors, effective immediately.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat passages and other diseased tissues, announced positive topline results from the company’s pharmacokinetic study of LYR-210.

Oncolytics Biotech® Inc. announced that the Company will present a corporate overview at the Ladenburg Thalmann Healthcare Conference, which is taking place virtually from July 13-14, 2021.

Theratechnologies Inc. announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday, July 15, 2021.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has participated in an important research project to develop a magnetic resonance (MR) imaging technique [1,2] that could potentially revolutionize the use of MR imaging in cardiology.

Nemaura Medical Inc. provided a business update and released financial results for the fiscal year ended March 31, 2021.

GenSight Biologics, a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, reported key efficacy and safety findings at 1.5 years post-treatment in the REFLECT Phase III clinical trial for LUMEVOQ®.

Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA ® (pembrolizumab)